AU-007 Showcases Unique IL-2 Class Profile with Promising Efficacy Data Aulos Bioscience, a pioneering company in the field of immuno-oncology, recently presented significant data supporting the dose selection for its lead therapeutic candidate, AU-007, at the 36th EORTC-NCI-AACR Symposium on…
Bioptimus’ H-optimus-0 Model Now Integrated with Proscia’s Concentriq® for Fast AI Development Bioptimus, a leading French AI startup, has announced the integration of its H-optimus-0 foundation model into Proscia’s Concentriq® Embeddings platform. With 1.1 billion parameters, H-optimus-0 is the largest…
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® in First-Line Treatment of Gastric, Gastroesophageal, and Esophageal Cancers BeiGene, a global oncology leader, has achieved a significant milestone with the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issuing…
Bruker Unveils Groundbreaking $100 Plasma Proteomics Platform, Pioneering Advances in Glycoproteomics and Metaproteomics Bruker Corporation has announced a revolutionary leap in 4D-Proteomics™, offering deep, high-fidelity plasma proteomics for just $100 per sample, marking a significant step forward in large-scale, unbiased…
NUCLIDIUM Announces First Patient Imaged in Phase 1 Study of ⁶¹Cu Radiotracer for Prostate Cancer NUCLIDIUM has successfully imaged the first patient in its Phase 1 clinical trial evaluating ⁶¹Cu-NuriPro™ (⁶¹Cu-NODAGA-PSMA I&T), a radiotracer designed to safely and accurately diagnose…
Celltrion has announced two-year findings from a post-hoc analysis of the LIBERTY studies (LIBERTY-CD and LIBERTY-UC), presented at United European Gastroenterology (UEG) Week 2024 in Vienna. The analysis shows that dose escalation of subcutaneous infliximab (CT-P13 SC) is effective for…
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has shared positive results from its Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, an investigational monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) during their first…
Medidata, a Dassault Systèmes brand and a leader in clinical trial solutions for the life sciences industry, has launched Medidata Rave Lite, an extension of its flagship clinical research software, Medidata Rave EDC. Designed specifically for Phase I and IV…
ClearB Therapeutics Licenses Novel Saponin Adjuvant TQL-1055, to Present Hepatitis B Vaccine Data at AASLD 2024 ClearB Therapeutics, a company focused on developing therapeutic vaccines for a functional cure of Hepatitis B, has licensed the novel saponin-based adjuvant TQL-1055 from…
Life Sciences Experts to Explore Global Collaboration, AI, and Clinical Trial Innovation at DIA Canada Annual Meeting The upcoming DIA Canada Annual Meeting, taking place on November 14-15 in Gatineau, Quebec, will gather life sciences leaders to discuss Canada’s precision…
Clarametyx Biosciences Moves Forward with Phase 2a Study of CMTX-101 for Cystic Fibrosis Infections Clarametyx Biosciences, Inc. has successfully completed the Phase 1b portion of its clinical trial for CMTX-101, a novel immune-enabling antibody therapy aimed at treating pulmonary infections…
Kezar Life Sciences Updates on Clinical Trials for Zetomipzomib Kezar Life Sciences, Inc. (Nasdaq: KZR), a biotechnology company focused on developing innovative therapeutics for immune-mediated diseases, has provided important updates on its clinical trials. The Independent Data Monitoring Committee (IDMC)…